NCT02490332

Brief Summary

The prevalence of otitis media among Greenlandic children is one of the highest in the world and twenty per cent of schoolchildren have impaired hearing in the frequencies for normal speech. Yet, there are no national guidelines to ensure prevention and treatment of recurrent acute otitis media and chronic otitis media with effusion and impaired hearing in Greenlandic children. International studies from the developed part of the world have shown that otitis prone children may benefit from tubulation of the tympanic membrane. However, it is unknown if these results can be applied to Greenlandic children. This PhD project will conduct a randomised controlled trial comparing tubulation of the tympanic membrane, in Greenlandic children aged 9-36 months with recurrent acute otitis media and/or chronic otitis media with effusion, to conservative treatment. The children will be followed for two years. Outcome measures will include number of visits to health clinics, number of tympanic membrane perforations, number of episodes with acute otitis media according to medical records, Quality of life, measured by the validated questionnaires OM6 and Caregiver Impact Questionnaire, number of episodes where per oral or intravenous antibiotics have been administered according to medical records and serious adverse events The trial will be conducted in collaboration with the Greenlandic health authorities and Copenhagen Trial Unit. With this trial the investigators hope to decrease the number of episodes with acute otitis media, the number of Greenlandic children with chronic perforations of the tympanic membrane and hearing impairment and increase quality of life. The results will add important knowledge to the effect of ventilation tube treatment also in an international aspect. There are to date only less than a handful of high quality studies concerning this issue on an international basis. The study will be among the first addressing this problem among populations with high risk of otitis media and is also of interest to other indigenous populations and the developing part of the world.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
31

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2016

Longer than P75 for not_applicable

Geographic Reach
1 country

6 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 3, 2015

Completed
1 month until next milestone

First Posted

Study publicly available on registry

July 3, 2015

Completed
7 months until next milestone

Study Start

First participant enrolled

February 1, 2016

Completed
4.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 2, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 2, 2020

Completed
Last Updated

November 4, 2020

Status Verified

November 1, 2020

Enrollment Period

4.8 years

First QC Date

June 3, 2015

Last Update Submit

November 2, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Number of visits to health clinic

    Assessed by investigating medical records.

    Two years after randomisation

Secondary Outcomes (4)

  • Number of episodes of acute otitis media

    Two years after randomisation

  • Quality of life

    Assessed at baseline, three months after randomisation, one year after randomisation, and at the end of the trial two years after randomisation

  • Number of episodes where per oral or intravenous antibiotics have been administered

    Two years after randomisation

  • Proportion of children with uni- or bilateral tympanic membrane perforations

    Two years after randomisation

Other Outcomes (2)

  • Number of episodes of aural discharge

    Two years after randomisation

  • Serious adverse events

    During the trial

Study Arms (2)

Ventilation tube treatment

EXPERIMENTAL

Ventilation tube insertion in the tympanic membrane

Device: Ventilation tube treatment

Conservative treatment

NO INTERVENTION

Conventional treatment

Interventions

Tympanostomy

Also known as: Donaldson myringotomy tube
Ventilation tube treatment

Eligibility Criteria

Age9 Months - 36 Months
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)

You may qualify if:

  • Children aged 9-36 months.
  • Children with at least one Greenlandic born parent with at least one Greenlandic born parent
  • American Society of Anaesthesiologists physical status classification class 1 and 2
  • B- or C2 - type curve measured by tympanometry at two visits three-four months apart or three episodes of acute otitis media in six months according to medical records or four episodes of acute otitis media in 12 months according to medical records

You may not qualify if:

  • Children with orofacial cleft, Downs syndrome or known generalised immune deficiency
  • American Society of Anaesthesiologists physical status classification class \> 2.
  • Lack of signed informed consent, signed by the legal guardian.
  • Description of experimental and control intervention Experimental intervention: The intervention group will be treated with bilateral Donaldson ventilation tubes administered in general anaesthesia Control intervention: The control intervention is based on the current practice in Greenland, which includes systemic antibiotic treatment as well as aural toilette and topical antibiotics. Ventilation tube insertion during the study period is not accepted in the control group.
  • Children in the intervention group as well as the control group will be seen once a year by the visiting ear-nose-and throat (ENT)-specialist and have a final consultation after at least two years after randomisation.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (6)

Aasiaat Regional Hospital

Aasiaat, Danmark, 3950, Greenland

Location

Ilulissat Regional Hospital

Ilulissat, Danmark, 3952, Greenland

Location

Nuuk Health Center

Nuuk, Danmark, 3900, Greenland

Location

Sisimiut Regional Hospital

Sisimiut, Danmark, 3912, Greenland

Location

Tasiilaq Health Center

Tasiilaq, Danmark, 3913, Greenland

Location

Qaqortoq Regional Hospital

Qaqortoq, 3920, Greenland

Location

Related Publications (2)

  • MacKeith S, Mulvaney CA, Galbraith K, Webster KE, Connolly R, Paing A, Marom T, Daniel M, Venekamp RP, Rovers MM, Schilder AG. Ventilation tubes (grommets) for otitis media with effusion (OME) in children. Cochrane Database Syst Rev. 2023 Nov 15;11(11):CD015215. doi: 10.1002/14651858.CD015215.pub2.

  • Demant MN, Jensen RG, Jakobsen JC, Gluud C, Homoe P. The effects of ventilation tubes versus no ventilation tubes for recurrent acute otitis media or chronic otitis media with effusion in 9 to 36 month old Greenlandic children, the SIUTIT trial: study protocol for a randomized controlled trial. Trials. 2017 Jan 19;18(1):30. doi: 10.1186/s13063-016-1770-x.

MeSH Terms

Conditions

Otitis Media

Condition Hierarchy (Ancestors)

OtitisEar DiseasesOtorhinolaryngologic Diseases

Study Officials

  • Malene N Demant, MD

    Køge University Hospital

    PRINCIPAL INVESTIGATOR
  • Preben Homoe, MD, PhD

    Køge University Hospital

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, PhD-student

Study Record Dates

First Submitted

June 3, 2015

First Posted

July 3, 2015

Study Start

February 1, 2016

Primary Completion

November 2, 2020

Study Completion

November 2, 2020

Last Updated

November 4, 2020

Record last verified: 2020-11

Data Sharing

IPD Sharing
Will share

The final dataset will be publically available in depersonalised format after the end of trial on the Danish Data Archive and ZENODO.

Locations